Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

• Auteurs principaux: Hsiangkuo Yuan (Auteur), Fred Cohen (Auteur), Maurice T Driessen (Auteur), Lynda J Krasenbaum (Auteur), Mario Ortega (Auteur), Mary Hopkins (Auteur), Michael J Marmura (Auteur)
• Format: Livre
• Publié: SAGE Publishing, 2024-03-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). Methods: This was a single-center, retrospective, observat...